In this IJGC podcast, Dr. Pedro Ramirez discusses PEACOCC Trial: Pembrolizumab in Clear Cell Cancer with Rebecca Kristeleit.

Rebecca Kristeleit is a Consultant Medical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust and an Adjunct Associate Professor in the Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences at KCL, London. She is Research Lead for gynaecological cancer, R&D Lead for Oncology and Clinical Lead for Oncology and Haematology Clinical Trials at Guy’s and St Thomas’ NHS Foundation Trust. She works as a Principle Investigator within the KCL Cancer Early Phase Trials Unit, Theme Lead within King’s Health Partners ECMC and is Academic Lead for the King’s Health Partners Gynaecological Cancer Biobank.  Rebecca has extensive experience in experimental therapeutics and associated translational research, particularly molecular selection for therapeutics, as well as Phase II and III clinical trials. She works closely with several academic collaborators at KCL, nationally and internationally. She is currently leading two trial programmes of drugs discovered at KCL, a novel immunotherapy and a solid tumour CAR-T. She mentors and supervises KCL undergraduate and postgraduate students. Rebecca’s primary motivation is to improve treatment options available for patients with gynaecological cancer and she has been instrumental in the development and delivery of new licensed drugs in gynaecological cancer, for example rucaparib, dostarlimab, through clinical trial research leadership. She led the UK academic PEACOCC trial investigating pembrolizumab in clear cell gynaecological cancer and is global Co-Investigator for DOVE, a follow-on international randomised Phase II trial in the same rare indication. She leads many trials nationally and internationally, several in partnership with GTG-UK. Rebecca has published extensively, speaks regularly at International Conferences and has held several national and international research leadership positions including Chair BGCS Scientific Committee, BGCS guidelines committee, BGCS medical oncology representative, Oncology and Haematology Expert Advisory Group for the Commission on Human Medicines, CRUK New Agents Committee, ESMO Faculty, Chair ASCO Gynaecological Cancer Scientific Committee, ASCO educational committee.